Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial

Expert Review of Clinical Immunology

Volumn 8, Issue 8, 2012, Pages 707-717

  Baş, Murat ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

acute treatment; B2 receptor antagonist; bradykinin; FAST 3; hereditary angioedema; icatibant; self administration

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; ICATIBANT; PLACEBO;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; LARYNX DISORDER; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN PAIN; SKIN SWELLING; STUDY DESIGN; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; DISEASE PROGRESSION; FEMALE; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84869834694     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.67     Document Type: Article

References (50)

1. Reshef A, Leibovich I, Goren A. Hereditary angioedema: New hopes for an orphan disease. Isr. Med. Assoc. J. 10(12), 850-855 (2008).
2. Bowen T, Cicardi M, Farkas H et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma. Clin. Immunol. 6(1), 24 (2010).
3. Riedl M, Gower RG, Chrvala CA. Current medical management of hereditary angioedema: Results from a large survey of US physicians. Ann. Allergy Asthma Immunol. 106(4), 316-322.e4 (2011).
4. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: A broad review for clinicians. Arch. Intern. Med. 161(20), 2417-2429 (2001). (Pubitemid 33043115)
5. Agostoni A, Aygören-Pürsün E, Binkley KE et al. Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol. 114(Suppl. 3), S51-S131 (2004).
6. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 351(9117), 1693-1697 (1998). (Pubitemid 28254530)
7. Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J. Allergy Clin. Immunol. 104(6), 1321-1322 (1999). (Pubitemid 30004997)
8. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N. Engl. J. Med. 347(8), 621-622 (2002).
9. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int. Immunopharmacol. 3(3), 311-317 (2003). (Pubitemid 36293959)
10. Banerji A. Current treatment of hereditary angioedema: An update on clinical studies. Allergy Asthma Proc. 31(5), 398-406 (2010).
11. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: A long-term survey of 118 patients. Ann. Allergy Asthma Immunol. 100(2), 153-161 (2008). (Pubitemid 351238551)
12. Dewald G, Bork K. Missense mutations in the coagulation Factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem. Biophys. Res. Commun. 343(4), 1286-1289 (2006).
13. Bork K, Kleist R, Hardt J, Witzke G. KallikreinYkinin system and fibrinolysis in hereditary angioedema due to Factor XII gene mutation Thr309Lys. Blood Coagul. Fibrinolysis 20(5), 325-332 (2009).
14. Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch. Intern. Med. 163(10), 1229-1235 (2003). (Pubitemid 36613077)
15. Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J. Am. Dent. Assoc. 134(8), 1088-1094 (2003). (Pubitemid 38175476)
16. Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus. Apher. Sci. 29(3), 235-238 (2003). (Pubitemid 37315588)
17. Zuraw BL. Current and future therapy for hereditary angioedema. Clin. Immunol. 114(1), 10-16 (2005). (Pubitemid 39642785)
18. Bowen T, Cicardi M, Farkas H et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J. Allergy Clin. Immunol. 114(3), 629-637 (2004). (Pubitemid 39194940)
19. Zuraw BL, Christiansen SC. New promise and hope for treating hereditary angioedema. Expert Opin. Investig. Drugs 17(5), 697-706 (2008). (Pubitemid 351843614)
20. Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 353(9158), 1066-1067 (1999). (Pubitemid 29149920)
21. Zuraw BL. HAE therapies: Past present and future. Allergy Asthma. Clin. Immunol. 6(1), 23 (2010).
22. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: Role of bradykinin. Allergy 62(8), 842-856 (2007). (Pubitemid 47037860)
23. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N. Engl. J. Med. 363(6), 532-541 (2010).
24. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N. Engl. J. Med. 287(9), 452-454 (1972).
25. Gadek JE, Hosea SW, Gelfand JA et al. Replacement therapy in hereditary angioedema: Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N. Engl. J. Med. 302(10), 542-546 (1980). (Pubitemid 10184278)
26. Cicardi M, Levy RJ, McNeil DL et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N. Engl. J. Med. 363(6), 523-531 (2010).
27. Levy RJ, Lumry WR, McNeil DL et al. EDEMA4: A Phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann. Allergy Asthma Immunol. 104(6), 523-529 (2010).
28. Lumry WR, Li HH, Levy RJ et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: The FAST-3 trial. Ann. Allergy Asthma Immunol. 107(6), 529-537 (2011).
29. Lunn M, Santos C, Craig T. Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: Approval, efficacy and safety. J. Blood Med. 1, 163-170 (2010).
30. Pedersen CM, Schmidt MR, Barnes G et al. Bradykinin does not mediate remote ischaemic preconditioning or ischaemiareperfusion injury in vivo in man. Heart 97(22), 1857-1861 (2011).
31. Bas M, Greve J, Stelter K et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: A case series. Ann. Emerg. Med. 56(3), 278-282 (2010).
32. Boccon-Gibod I, Bouillet L. Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin. Exp. Immunol. 168(3), 303-307 (2012).
33. Vitrat-Hincky V, Gompel A, Dumestre-Perard C et al. Type III hereditary angio-oedema: Clinical and biological features in a French cohort. Allergy 65(10), 1331-1336 (2010).
34. Zanichelli A, Bova M, Coerezza A, Petraroli A, Triggiani M, Cicardi M. Icatibant treatment for acquired C1-inhibitor deficiency: A real-world observational study. Allergy 67(8), 1074-1077 (2012).
35. Zhang W, Bhola N, Kalyankrishna S et al. Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol. Cancer Res. 6(12), 1946-1956 (2008).
36. Dlamini Z, Bhoola KD. Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. J. Clin. Pathol. 58(9), 915-922 (2005). (Pubitemid 41265274)
37. Stewart JM, Gera L, York EJ, Chan DC, Bunn P. Bradykinin antagonists: Present progress and future prospects. Immunopharmacology 43(2-3), 155-161 (1999).
38. Stewart JM, Gera L, Chan DC et al. Combination cancer chemotherapy with one compound: Pluripotent bradykinin antagonists. Peptides 26(8), 1288-1291 (2005). (Pubitemid 41021461)
39. Song JS, Sainz IM, Cosenza SC et al. Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood 104(7), 2065-2072 (2004). (Pubitemid 39297858)
40. Stewart JM, Gera L, Chan DC et al. New lung cancer drugs from bradykinin antagonists. Chest 125(Suppl. 3), 148S (2004). (Pubitemid 38648359)
41. Stewart JM, Chan DC, Simkeviciene V et al. Bradykinin antagonists as new drugs for prostate cancer. Int. Immunopharmacol. 2(13-14), 1781-1786 (2002). (Pubitemid 35373921)
42. Rosenwasser L. New insights into the pathophysiology of allergic rhinitis. Allergy Asthma Proc. 28(1), 10-15 (2007).
43. Akbary AM, Wirth KJ, Schölkens BA. Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 33(1-3), 238-242 (1996). (Pubitemid 26247939)
44. Cruden NL, Newby DE. Therapeutic potential of icatibant (HOE-140, JE-049). Expert Opin. Pharmacother. 9(13), 2383-2390 (2008).
45. Barratt-Due A, Johansen HT, Sokolov A et al. The role of bradykinin and the effect of the bradykinin receptor antagonist icatibant in porcine sepsis. Shock 36(5), 517-523 (2011).
46. Kansui Y, Fujii K, Goto K, Abe I. Bradykinin enhances sympathetic neurotransmission in rat blood vessels. Hypertension 39(1), 29-34 (2002). (Pubitemid 34098084)
47. Cicardi M, Bork K, Caballero T et al.; HAWK (Hereditary Angioedema International Working Group). Evidencebased recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 67(2), 147-157 (2012).
48. Bouillet L, Boccon-Gibod I, Ponard D et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann. Allergy Asthma Immunol. 103(5), 448 (2009).
49. Marqués L, Domingo D, Maravall FJ, Clotet J. Short-term prophylactic treatment of hereditary angioedema with icatibant. Allergy 65(1), 137-138 (2010).
50. Varga L, Farkas H. rhC1INH: A new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev. Clin. Immunol. 7(2), 143-153 (2011